Fibrocell Science Inc. (FCSC) Shares Bought by Janney Montgomery Scott LLC
Janney Montgomery Scott LLC boosted its position in shares of Fibrocell Science Inc. (NASDAQ:FCSC) by 54.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 172,932 shares of the company’s stock after buying an additional 61,050 shares during the period. Janney Montgomery Scott LLC owned 0.39% of Fibrocell Science worth $199,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in FCSC. Geode Capital Management LLC boosted its position in Fibrocell Science by 1.2% in the first quarter. Geode Capital Management LLC now owns 208,175 shares of the company’s stock worth $520,000 after buying an additional 2,551 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its position in Fibrocell Science by 31.4% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 250,803 shares of the company’s stock worth $288,000 after buying an additional 59,926 shares during the period. Finally, State Street Corp raised its position in Fibrocell Science by 26.7% in the first quarter. State Street Corp now owns 292,377 shares of the company’s stock worth $733,000 after buying an additional 61,636 shares during the period. Institutional investors own 61.89% of the company’s stock.
Fibrocell Science Inc. (NASDAQ:FCSC) traded up 0.0385% during mid-day trading on Wednesday, hitting $0.7802. The company’s stock had a trading volume of 143,087 shares. The company’s market cap is $34.25 million. The firm’s 50-day moving average is $0.95 and its 200-day moving average is $1.70. Fibrocell Science Inc. has a 12-month low of $0.78 and a 12-month high of $6.58.
Fibrocell Science (NASDAQ:FCSC) last released its earnings results on Thursday, August 4th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.03. Fibrocell Science had a negative net margin of 10,860.23% and a negative return on equity of 124.33%. Analysts predict that Fibrocell Science Inc. will post ($0.49) EPS for the current fiscal year.
A number of research analysts recently weighed in on FCSC shares. Roth Capital started coverage on Fibrocell Science in a research report on Thursday, May 26th. They set a “buy” rating and a $7.00 price objective for the company. Zacks Investment Research lowered Fibrocell Science from a “buy” rating to a “hold” rating in a research report on Thursday, May 26th. Canaccord Genuity reaffirmed a “buy” rating and set a $1.50 price objective on shares of Fibrocell Science in a research report on Wednesday, June 8th. Wedbush reaffirmed a “neutral” rating and set a $4.00 price objective (up previously from $1.50) on shares of Fibrocell Science in a research report on Wednesday, June 8th. Finally, Griffin Securities reaffirmed a “buy” rating and set a $12.00 price objective on shares of Fibrocell Science in a research report on Wednesday, July 6th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $4.75.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Want to see what other hedge funds are holding FCSC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fibrocell Science Inc. (NASDAQ:FCSC).
Receive News & Ratings for Fibrocell Science Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.